In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).

Unlike rabies, which causes roughly 59,000 human deaths annually, predominantly in Africa and Asia, human infection with bat ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

In a bold move that could reshape the future of biomedical research, Boster Bio is launching a Free Antibody Validation ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

India has achieved a significant 75% reduction in rabies-related deaths, with a government plan to eliminate fatalities by ...

At a recent Senate hearing, Health and Human Services Secretary Robert F. Kennedy Jr. said something I never thought I’d hear ...

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...